Olmetec Plus (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxomil, the active ingredient in Olmetec Plus, is an angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension, often in combination with a diuretic, and is prescribed for adults. GNH USA supplies Olmetec Plus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olmetec Plus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmetec Plus combines an ARB with a thiazide diuretic to lower blood pressure through complementary mechanisms.

- Hypertension: helps achieve target blood pressure levels in adults. - Heart failure: supports fluid management and blood pressure control when used as part of a broader regimen. - Diabetic nephropathy: assists in reducing intraglomerular pressure, slowing kidney damage progression.

Adverse reactions to Olmetec Plus are reported across a spectrum of frequency.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal upset

Serious or Rare Side Effects: - Severe hypotension - Acute kidney injury - Hyperkalemia - Angio‑edema - Liver enzyme elevations - Blood dyscrasias (e.g., agranulocytosis)

Olmetec Plus should be used with careful clinical oversight, particularly in patients with certain comorbidities.

- Renal impairment: monitor kidney function and electrolytes regularly. - Hepatic disease: use caution; adjust dosing if necessary. - Electrolyte imbalance: check serum potassium and sodium levels. - Pregnancy: contraindicated in the second and third trimesters; avoid use. - Concomitant potassium‑sparing agents: risk of hyperkalemia, monitor closely. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olmetec Plus may interact with several drug classes, requiring monitoring or avoidance.

Major Interactions (Avoid): - Aliskiren (in diabetics): increased risk of renal dysfunction and hyperkalemia. - Potassium supplements or potassium‑sparing diuretics: may cause dangerous hyperkalemia. - NSAIDs (e.g., ibuprofen, naproxen): can blunt antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - Lithium: may increase lithium levels, risking toxicity. - Antidiabetic agents: enhanced glucose‑lowering effect, risk of hypoglycaemia. - ACE inhibitors or other ARBs: additive effect on potassium and renal function.